Adcendo

Adcendo

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $191M

Overview

Adcendo is a clinical-stage biotechnology company pioneering novel antibody-drug conjugate (ADC) therapies for cancers with significant unmet need. Its lead candidate, ADCE-D01, targeting uPARAP for soft tissue sarcoma, has entered Phase I/II trials and received FDA Fast Track designation, highlighting its potential. The company is led by a seasoned management team with direct experience in developing and commercializing multiple approved ADC drugs, positioning it strongly in the competitive oncology landscape.

Oncology

Technology Platform

Focus on developing antibody-drug conjugates (ADCs) through deep understanding of novel target biology (particularly endocytic receptors like uPARAP) combined with optimized linker-payload technologies.

Funding History

3
Total raised:$191M
Series B$109M
Series A$31M
Series A$51M

Opportunities

The FDA Fast Track designation for ADCE-D01 in soft tissue sarcoma accelerates its development path in a market with high unmet need.
The novel uPARAP target also presents potential for expansion into other mesenchymal cancers, broadening the addressable patient population.

Risk Factors

Clinical development risk is paramount, as failure in Phase I/II trials would significantly impact valuation.
The company faces intense competition in the ADC space from larger, resource-rich players and is dependent on raising additional capital to fund operations through key milestones.

Competitive Landscape

Adcendo competes in the crowded and fast-growing field of ADC oncology therapeutics, dominated by large pharma (e.g., AstraZeneca/Daiichi Sankyo, Gilead) and other biotech innovators. Its differentiation strategy relies on targeting novel biology (uPARAP) not addressed by existing ADCs to carve out a niche in specific sarcoma subtypes.